Fig. 1: Immunization scheme and study design. | npj Vaccines

Fig. 1: Immunization scheme and study design.

From: Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

Fig. 1

a Volunteers were immunized with SumayaVAC-1 (full length MSP1 plus GLA-SE as adjuvant, 500 µl volume) on days 0, 29, 57, and optionally after unblinding of the cohort on day 182. Blood samples were taken for serological analysis on the days indicated. The safety follow-up was scheduled 6 months after the last vaccination. b 32 healthy volunteers were recruited in two consecutive cohorts. Sixteen volunteers each were randomly assigned within a cohort. The number of volunteers receiving three or four vaccinations is indicated for each cohort.

Back to article page